Related Experiment Video
Updated: May 22, 2026
08:48
Using Live Cell STED Imaging to Visualize Mitochondrial Inner Membrane Ultrastructure in Neuronal Cell Models
Published on: June 30, 2023
Mitochondrial dysfunction--a pharmacological target in Alzheimer's disease
Gunter P Eckert1, Kathrin Renner, Schamim H Eckert
1Department of Pharmacology, Biocenter, Campus Riedberg, Goethe-University, Biocentre Geb. N260, R.1.09, Max-von-Laue Str. 9, 60438 Frankfurt, Germany. g.p.eckert@em.uni-frankfurt.de
Molecular Neurobiology
|May 4, 2012
Summary
Mitochondrial dysfunction is key in Alzheimer's disease (AD) pathogenesis. Early therapeutic interventions targeting mitochondria are crucial, as later treatments show limited success in clinical trials.
Area of Science:
- Neuroscience
- Biochemistry
- Pathology
Background:
- Mitochondrial dysfunction is increasingly implicated in neurodegenerative diseases like Alzheimer's disease (AD).
- Key issues include altered mitochondrial content, respiratory enzyme function, oxidative stress, and apoptosis.
- Mitochondrial network structure and bioenergetic function are critical research areas.
Purpose of the Study:
- To review mitochondria-targeting compounds for Alzheimer's disease (AD).
- To analyze the efficacy of these compounds based on preclinical and clinical data.
- To discuss the timing of therapeutic interventions in AD progression.
Main Methods:
- Literature review of preclinical and clinical studies.
- Analysis of compounds targeting mitochondrial function in AD models.
- Evaluation of clinical trial outcomes for mitochondria-targeting drugs.
Main Results:
- Numerous compounds (e.g., dimebon, methylene blue, curcumin) show preclinical promise for AD.
- Most clinical trials for these compounds have not met expectations.
- Preclinical benefits often do not translate to clinical efficacy.
Conclusions:
- Mitochondrial dysfunction is an early event in Alzheimer's disease (AD) progression.
- Pharmacological interventions may be ineffective if administered too late in the disease.
- Future research should focus on early-stage therapeutic strategies for AD.
More Related Videos
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:46Electron Transport Chain: Complex I and II
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...